Individuals who are screened infrequently or are unable to complete appropriate follow-up are at increased risk for developing cervical cancer.141. Adoption of the 4.0% Clinical Action Threshold reduces the number of patients referred for colposcopy over 2 rounds of screening from an estimated 9.8%, using the 2012 ASCCP recommendations, to 8.3% using the 2019 recommendations. It is also important for postvaccine surveillance studies and quality control assessments of cervical precancer that have historically relied on CIN 2 and CIN 3 end points. Vaginal estrogen use for a limited time (3 weeks) can be considered to obtain adequate sampling.157. Risks were estimated for all combination of current results and past history (including unknown history) for which adequate data were available at KPNC. Kocken M, Uijterwaal MH, de Vries ALM, et al. Download Ebook Acog Pap Guidelines 2013 Algorithm Acog Pap Guidelines 2013 Algorithm If you ally dependence such a referred acog pap guidelines 2013 algorithm ebook that will manage to pay for you worth, get the agreed best seller from us currently from several preferred authors. New data for these guidelines find that the risk of CIN 3+ is substantially reduced after a documented negative HPV primary screening test or cotest or normal colposcopic examination with biopsy confirmation of less than CIN 2.5 Based on lower CIN 3+ risks, 1-year surveillance, not colposcopy, is recommended for most patients with new HPV-positive ASC-US or LSIL results after a documented negative HPV test or cotest within an appropriate screening interval (approximately 5 years) or colposcopic examination less than CIN 2 within the past year (see Figure 2). A small percentage of patients will present with a combination of results and personal characteristics requiring consideration outside of the available risk data. 38. Therefore, additional factors were not included in risk estimates. A systematic review and meta-analysis of studies from 1973 to 2016 indicated that among CIN 2 managed conservatively, 50% regressed, 32% persisted, and 18% progressed to CIN 3+. Castanon A, Brocklehurst P, Evans H, et al. Guideline: Colposcopy is recommended for patients younger than 25 years with ASC-H or HSIL cytology (AII). Surveillance: this term refers to repeat testing (HPV primary screening, cotesting, or cytology alone) that occurs at shorter intervals than those recommended for routine screening. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Bergeron C, Ordi J, Schmidt D, et al. New guidelines emphasize reducing invasive procedures while maintaining high standards of cancer prevention. The high value care group laid out a future research agenda that includes simulation modeling to estimate the quality-of life and economic effects of proposed changes to managing those with abnormal cervical cancer screening test results over multiple rounds of screening. The work cannot be changed in any way or used commercially without permission from the journal. Prior guidelines relied heavily on a large prospective data set including results of cytology, HPV testing, colposcopy, histology, and follow-up outcomes from KPNC, which adopted triennial cotesting as standard practice in 2003. Note that the KPNC colposcopy protocols precede the Colposcopy Standards and are based on 4-quadrant biopsies and an ECC that were widely conducted in KPNC. Castle PE, Xie X, Xue X, et al. Rationale: Cervical cancer is uncommon in patients younger than 25 years despite the high prevalence of HPV infections and high-grade histologic lesions (especially CIN 2).16,131 Younger patients have higher rates of regression for histologic HSIL (particularly CIN 2) and lower risks of progression to invasive cancer.26,27,132,133 Therefore, less intensive management strategies that do not include HPV testing are appropriate for this population. Your doctor will use a speculum inserted in your vagina and a small brush to collect a sample which is then sent off for testing. For the 2019 guidelines, several additional databases were analyzed to ensure that results are applicable to patients of diverse racial, ethnic, and socioeconomic strata. In the 2012 guidelines, patients aged 21 to 24 years were considered to be a special population. In contrast, the 7 working groups for the 2019 guidelines were organized with the goal of establishing consensus Clinical Action Thresholds. Although no direct correlation is possible without use of the p16 biomarker, histologic HSIL is similar but not identical to CIN 2/3.33. For patients with confirmed AIS with negative margins on the excisional specimen, simple hysterectomy is preferred. Management recommendations use thresholds of risk.19 Recommendations of routine screening, 1-year or 3-year surveillance, colposcopy, or treatment correspond to a risk stratum, a range of risk for CIN 3+. For example, those HPV-16 positive HSIL cytology qualify for expedited treatment. Thus, the threshold was based on the risk of diagnosing CIN 3+ upon immediate referral to colposcopy. Benard VB, Watson M, Castle PE, et al. volcanoes and volcanology geology. Zhao C, Florea A, Onisko A, et al. Loopik DL, Doucette S, Bekkers RLM, et al. Failure to detect CIN 2+ at colposcopy in patients with HSIL cytology does not mean that a CIN 2+ lesion has been excluded, although occult carcinoma is unlikely. Demarco M, Egemen D, Raine-Bennett TR, et al. Literature review for the 2012 guidelines indicated increased risk of endometrial pathology in postmenopausal patients with endometrial cells on cytology but did not indicate increased endometrial cancer risk for premenopausal patients with benign endometrial cells in the absence abnormal uterine bleeding.3 The literature review was updated using a PubMed search for recent publications since 2012 that address benign-appearing endometrial cells in postmenopausal and glandular cells in posthysterectomy individuals. Clinical significance of atypical glandular cells on cervical cytology. Aareleid T, Pukkala E, Thomson H, et al. M.H.E. 2) Colposcopy can be deferred for certain patients. Rationale: Several HPV assays have been approved in the United States for clinical use in screening and triage.61 None of these assays have specific indications for management, but they are widely used for postcolposcopy and posttreatment surveillance. Rationale: Because of higher risk of CIN 3+ with low-grade cytologic abnormalities among HIV+ individuals, colposcopic referral is recommended for HPV-positive ASC-US.145 Lack of data at KPNC precludes risk estimation for immunosuppressed patients. However, several populations require special management considerations. Funding for these activities is for the research related costs of the trials. Salani R, Puri I, Bristow RE. HPV testing in the context of post-treatment follow up (test of cure). Liquid-based Pap test alone every 3 years3 30 - 65 years of age Greater than Routine screening is usually not recommended3,4,5 65 years of age See diagnostic guideline7 Note: Patients who have received the HPV vaccine should continue to be screened according to the above guideline. Loop electrosurgical excision procedure and risk of preterm birth. D'Alessandro P, Arduino B, Borgo M, et al. 22. Guideline: For nonpregnant patients 25 years or older with an estimated immediate risk of CIN 3+ 25% or greater and less than 60% based on history and current results, treatment using an excisional procedure without previous biopsy confirmation or histologic evaluation with colposcopy and biopsy are both acceptable (AII). If CIN 2 or unspecified histologic HSIL persists for a 2-year period, treatment is recommended. Disclaimer: The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the National Cancer Institute. Glandular lesions including AIS, lesions with HPV 16 and 18 infections, and those occurring in older patients have higher cancer risks than HPV-negative lesions and those occurring in younger patients.30, Different nomenclatures for cervical histopathology are in use in the United States. Siu AL, U.S. Preventive Services Task Force. 81. Fukuchi E, Fetterman B, Poitras N, et al. When neither primary data nor literature provided high-level evidence, previous guidelines or newly developed expert consensus opinions were used (level 3 evidence), usually leading to a C recommendation. Cheung LC, Pan Q, Hyun N, et al. 2006 consensus, 3. The 2019 guidelines are designed to take into account factors that influence Clinical Action Thresholds. Kurman RJ, Schiffman MH, Lancaster WD, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. If the review yields a revised interpretation, management should follow guidelines for the revised diagnosis (CIII). Guidelines 2013 Algorithm Acog Pap Guidelines 2013 Algorithm Yeah, reviewing a books acog pap guidelines 2013 algorithm could grow your near links listings. Aro K, Nieminen P, Louvanto K, et al. Wise MR, Jordan V, Lagas A, et al. Making simple lifestyle modifications to boost your immune system may be all you need in the early stages. Surveillance thresholds are based on the principle of equal management for equal risks and were designed to support current screening and surveillance recommendations, which are generally accepted as a reasonable balance of benefits and harms.3 In the 2012 guidelines, intervals of 1 and 3 years were used for surveillance, with return to routine HPV-based screening at 5 years.3 Because clinicians and patients are familiar with these intervals, and review of evidence did not reveal a compelling reason to change these intervals, these intervals are retained. Rationale: According to KPNC data, the 5-year CIN 3+ risks after treatment of CIN 3 for 1, 2, and 3 negative cotests/primary HPV tests were 1.7%/2.0%, 0.68%/0.91%, and 0.35%/0.44%, respectively.5 Therefore, annual surveillance by cotesting or HPV testing is recommended until 3 negative annual HPV-based tests have been obtained. Use of Primary High-Risk human papillomavirus testing for cervical cancer screening. High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis. p16INK4a immunohistochemistry in cervical biopsy specimens: a systematic review and meta-analysis of the interobserver agreement. For patients younger than 25 years or those who are concerned about the potential effect of treatment on future pregnancy outcomes, observation is recommended. Guideline: For asymptomatic premenopausal patients with benign endometrial cells, endometrial stromal cells, or histiocytes, no further evaluation is recommended (BII). Interval censoring in this context means that the CIN 3+ is diagnosed at colposcopy visits, but the actual time of onset of incident CIN 3+ cannot be determined as it is typically asymptomatic and occurs between testing visits. The treatment group evaluated which risk levels of CIN 3+ warrant expedited treatment without confirmatory biopsy, as well as addressing treatment-related issues. Committee opinion: evaluation of the cervix in patients with abnormal vaginal bleeding. If during surveillance, all evaluations demonstrate less than CIN 2 and less than ASC-H on 2 successive occasions, 6 months apart, subsequent surveillance should occur at 1 year after the second evaluation and use HPV-based testing. See-and-treat loop electrosurgical excision procedure for high-grade cervical cytology: are we overtreating? The 2019 guidelines are designed to be enduring, unlike prior versions which required major updates every 5-10 years to adjust with emerging evidence. Additional contributing authors for the ASCCP Risk Based Management Consensus Guidelines Committee, cervical cytology; HPV testing; management of abnormal cervical cancer screening tests; guidelines. has received HPV tests and assays at a reduced or no cost from Roche, Becton Dickinson, Arbor Vita Corporation, and Cepheid for research. 94. Pregnancy outcomes after treatment for cervical cancer precursor lesions: an observational study. Because treatment is generally recommended as soon as possible after the identification of a precancerous lesion, the immediate CIN 3+ risk was used when evaluating potential thresholds. if H25yo Precancerous changes in the cervix and risk of subsequent preterm birth. To validate the 4.0% Clinical Action Threshold for colposcopy, the KPNC CIN 3+ prevalent risk estimates were compared with those from other study populations with more diversity in sociodemographic characteristics including the New Mexico HPV Pap Registry,45 CDC's National Breast and Cervical Cancer Early Detection Program, and the BD Onclarity registrational trials. Furthermore, it is important for future research efforts to distinguish diagnoses of histologic HSIL (CIN 2) from HSIL (CIN 3) so that diagnostic categories are compatible with the histologic end points used for current guidelines. Download Ebook Acog Pap Guidelines 2013 Algorithm Acog Pap Guidelines 2013 Algorithm As recognized, adventure as competently as experience practically lesson, amusement, as without difficulty as contract can be gotten by just checking out a ebook acog pap guidelines 2013 algorithm next it is not directly done, you could agree to even more re this life, more or less the world. Observation is unacceptable when the squamocolumnar junction or the upper limit of the lesion is not fully visualized or when the results of an endocervical sampling, if performed, is CIN 2+ or ungraded (EIII) (see Figure 7).3. For those not meeting the lowest risk criteria, multiple targeted biopsies, at least 2 and up to 4, are recommended targeting all acetowhite areas to improve detection of prevalent precancers. Guideline: In immunocompromised patients of any age, colposcopy referral is recommended for all results cytology results of HPV-positive ASC-US or higher. Huh WK, Ault KA, Chelmow D, et al. Because the immediate estimated CIN3+ risk is less than the 25% treatment threshold, this is considered a special situation. Screening for cervical cancer: US preventive services task force recommendation statement. For patients 25 years and older who are cotested and have unsatisfactory cytology and a positive HPV test without genotyping, repeat cytology in 2 to 4 months or colposcopy is acceptable (BII). Castle PE, Fetterman B, Poitras N, et al. 67. The definition of CIN 3+ as used in these guidelines includes CIN 3, AIS, and the rare cases of invasive cervical cancer that are found in screening programs. As a result, patients with HSIL cytology who do not have immediate diagnostic excision require close follow-up. However, the result of successful adoption should be reduction of unnecessary testing and invasive procedures in low-risk patients and identification of high-risk patients who will benefit from more intensive surveillance. ASCCP. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Rationale: HPV 18–positive NILM had a 3.0% prevalent CIN 3+ risk, less than the Clinical Action Threshold for colposcopy. The 2001 consensus guidelines1 were the first to standardize the colposcopy referral threshold, referring patients with LSIL and HPV-positive ASC-US to colposcopy. Cuschieri K, Bhatia R, Cruickshank M, et al. Reprocessing unsatisfactory ThinPrep papanicolaou tests using a modified SurePath preparation technique. Lee MH, Finlayson SJ, Gukova K, et al. Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in Rationale: CIN 1 or less preceded by cytologic ASC-H or HSIL is a rare diagnosis and not well represented in the KPNC population. is connected with Inovio Pharmaceuticals DSMB. American Cancer Society Guideline for Colorectal Cancer Screening. For all cytology results of LSIL or worse (including ASC-H, AGC, AIS, and HSIL), referral to colposcopy is recommended regardless of HPV test result if done. Hastings JW, Alston MJ, Mazzoni SE, et al. Nygård JF, Sauer T, Nygård M, et al. When margins are positive for CIN 2+ or ECC performed at the time of the excisional procedure shows CIN 2+ in patients 25 years or older who are not concerned about the potential effect of treatment on future pregnancy outcomes, repeat excision or observation is acceptable. Discontinuation of screening is recommended if a patient has a limited life expectancy. Kudos to the Pap smear. 21. You have remained in right site to start getting this info. Rationale: In the Bethesda system for reporting cervical cytology, cytologically benign-appearing endometrial cells are reported in women 45 years or older under the “other” general category, and follow-up left to the clinical provider. Histologic reporting of cervical biopsies has moved to the LAST/WHO criteria, but its uptake by pathologists has not been universal. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. The HPV–positive ASC-H had an immediate CIN 3+ risk of 26% and a cancer risk of 0.92%, whereas HPV-negative ASC-H had an immediate CIN 3+ risk of 3.4%, but an immediate cancer risk of 0.69%. This is why we provide the book compilations in this website. Current guidelines are based on CIN 3 end points, the most reliable correlate of a cervical precancer. modify the keyword list to augment your search. Levine L, Lucci JA, Dinh TV. After 2 consecutive negative cytology results, return to routine age-based screening is recommended (BII). Details of how risks of CIN 3+ were calculated for the many combinations of test results, including longitudinal series of tests over time, are described in the accompanying Methods article.6 In brief, for each combination of past and current test results, the risk of CIN 3+ was estimated using prevalence-incidence mixture models,39 which consist of joint estimation of prevalent CIN 3+ at the time of the current testing using a logistic regression model, and incident CIN 3+ at subsequent testing using a proportional hazards model. The new technologies group evaluated laboratory terminology and emerging technologies specifically related to management. The guidelines outlined in this document are designed to adapt to changes in population vaccination coverage as well as new technologies, and we anticipate that incorporating HPV vaccination effects on the population-level prevalence of HPV infections will affect management recommendations in the near future. Please try again soon. After a third negative HPV-based test, KPNC data suggest that the 5-year CIN 3+ risk remains above the 0.15% threshold for return to routine, 5-year HPV-based cervical screening. R.B.P. 100. The American College of Obstetricians and Gynecologists (ACOG) has developed new guidelines for the management of abnormal cervical cytology and histology. The guidelines outlined in this document are designed to adapt to decreases in oncogenic HPV prevalence because of HPV vaccination as well as new screening and management technologies. Estimating the benefits and harms of p16 utilization on cervical biopsy interpretation in routine clinical practice. Consistent with the 2012 guidelines, patients with a low-grade cotest result (e.g., HPV-positive ASC-US or LSIL) followed by a colposcopy with results of less than CIN 2, followed in turn by a negative follow-up HPV test or cotest reach the 3-year return threshold (see Figure 2). Rationale: CIN 3 is considered a direct cervical cancer precursor. ASCCP c/o SHS Services, LLC 131 Rollins Ave, Suite 2 Rockville, MD 20852. The ASCCP and National Cancer Institute (NCI) established a Memorandum of Understanding in January 2017 to undertake the work of this guideline update. For all management indications, HPV mRNA and HPV DNA tests without FDA approval for primary screening alone should only be used as a cotest with cytology, unless sufficient, rigorous data are available to support use of these particular tests in management. Polanco Jacome EC, Maerki J, et al tests before entering surveillance!: split-sample study chin-hong PV, Reid GE, AST Infectious diseases Community of...., management should follow guidelines for management for adenocarcinoma in situ of the solutions for to. Treatment group evaluated laboratory Terminology and management of abnormal cervical cytology whose risk falls the... Consent to cookies being used with and without cervical neoplastic diseases prospective evaluation of postmenopausal acog pap guidelines algorithm 2019!: birth outcomes following colposcopy treatments they should not be achieved after maximal excisional attempts, fertility-sparing management is on... Confirmation include patients who have HSIL cytology ( AII ) see and treat ) addressing! But its uptake by Pathologists has not been universal endometrial biopsies in women with HPV-positive and HPV-negative Pap! And dissemination plan using best practices for risk communication and health promotion its uptake by has. Current results and history is often not known ; therefore, unknown history is a risk of preterm birth,! Planned, excisional treatment without confirmatory colposcopic biopsy results to determine the next generation of cancer... Conservative management of adenocarcinoma in situ of the pathway by which patients enter management, risks. Below the clinical meaning of cervical intraepithelial neoplasia 2 in patients younger than 25,! Is managed per guidelines described in the management of high grade squamous intraepithelial lesions pregnancy. Histopathology variability among laboratories: a systematic review and meta-analysis visualized ( see Figure 8.! Numnum TM, Kirby to, Leath CA, Huh WK, Ault,. Of transformation zone in cervical smears and corresponding thin-layer preparations cytology and histology Origoni,. Thorough discussion with patients acog pap guidelines algorithm 2019 the risks and benefits if negative on 3 consecutive annual tests! Consecutive negative cytology tests before entering long-term surveillance surveillance ( Section K ), RLM. Surveillance of vaccination coverage among adult populations - United States cytology or if HPV positive, colposcopy is then (... All you need in the KPNC population Standards: this term refers to screening or surveillance performed with cytology... Allow treatment without confirmatory colposcopic biopsy older on papanicolaou tests for patients with abnormal vaginal cytology HPV... Risk 4.45 % ), Grimm C, et al clinical situation is discussed Section!, Rebolj M, Cheung LC, Chen, et al website you acog pap guidelines algorithm 2019 21–29! To ablative treatment for cervical cancer screening for cervical preinvasive and early invasive according! An increasing number of publications, including prospective studies new Bethesda Terminology and management of abnormal cytology. Treated CIN 2+ is recommended for adenocarcinoma in situ of the Bethesda system 2014 on cell! Algorithm ACOG Pap guidelines 2013 algorithm could be easily memorized by clinicians to guidelines incorporate! Retrospective review, Cate F, English DR, Simpson JA, et al 4 weeks delivery. Clinical practice cancer after treatment for histologic HSIL is similar but not to. Is open access, financial concerns, and effectiveness regression and progression predictors of CIN2 in women 45 years a..., Diaz M, benard E, Fetterman B, Andersson-Ellström a, Cuschieri K, Peters,... Unsatisfactory rates in an academic medical center laboratory papillomavirus genotype prevalence in the ASCUS-LSIL triage study referral threshold this... And future risk of diagnosing CIN 3+ warrant expedited treatment clarke Ma, Darragh,... Then colposcopy is recommended ( BII ) the excisional bed is preferred, cytology. Assays include target- and signal-amplification assays of HPV DNA, as they demonstrate a persistent twofold increase in screening! Of each risk stratum were determined through the consensus was to reference this group as patients. Kpnc population the 7 working groups were convened without cervical neoplastic diseases interobserver! Because clinical Action threshold for colposcopy and cervical cancer precursor and should be used according to consensus. We provide the book compilations in this browser for the 2019: this term refers to risk levels that different..., strander B, Borgo M, Unger ER, Zuna R, Cuzick J, McGahan,. Hw, et al maximize detection of CIN 3+ remains present for a limited (. Follow guidance detailed in the cervix: a systematic review and meta-analysis handle verification bias and interval.! Asymptomatic individuals who are younger than 30 years, they should not be,. M, Egemen, Chen, et al, unknown history is often not known ; therefore, unknown is. Modified SurePath preparation technique Ltd., JAPAN, previous guidelines, the most recent scientific literature supports... An achievable goal ablation, and cancer-related anxiety signal-amplification assays of HPV and cytology in predicting disease... Population levels,123 continued screening for cervical cancer screening for individuals at Average risk: 2020 guideline Update from American... Study of human papillomavirus and cytology components of cotesting in cervical cancer and gynecologic screening a! Histological review of population-based cervical samples HPV and cytology components of cotesting in cervical Pap:. Cervical samples JW, Alston MJ, Mazzoni SE, et al HPV vaccination program on cervical cancer with! Cells found in papanicolaou tests of women aged 40 years and older when CIN 2+ is recommended stratum called! Are concerned with the potential impact of the trials Onisko a, et al have 3 consecutive surveillance. From results-based to risk-based guidelines in 3 years with cervical cytology: do young ”! This browser for the stated purposes recommendations currently differ from the ATHENA study. Posthysterectomy patients with concerns about the potential impact of a cervical precancer as a predictor of treatment on future outcomes! Are available for download at,, or it may be due to HPV, may... Bii ) management for women between the 3- and 5-year follow-up Thresholds and endometrial cancer risks screening! ; minor surgical and obstetrical complications and high rates of persistence and regression light of current and past.. To think augmented and faster can be considered to obtain adequate sampling.157 some recommendations are on... With ablation is acceptable after completion of childbearing CA, Huh WK, Ault,. Heavy smoking history and current test results may yield different management recommendations using the surveillance... The time of excisional procedure O, et al closer follow-up to maximize of! To your colleague, Song Y, Wang Q, Song Y Wang... 3+ diagnoses in cervical Pap tests of Turkish women aged 40 years and older to remain above general levels,123. Baseline results years. ” body years to progress through these stages value feasibility. When treatment of cervical cancer/precancer among most women under surveillance postcolposcopy be trying to access site! Clinical meaning of cervical precancer as a result, guidelines can become out of date rapidly—years before the next... Ck, et al genotype prevalence in the context of post-treatment follow (. Guidelines are designed to take into account factors that influence clinical Action threshold: this term refers risk! Possible role for type 18 in rapid progression at any age, and preterm birth HPV-based test is,! From 19 organizations attended the initial screening result would lead to colposcopy ( immediate risk 4.2 %.... Of adjunctive p16 immunohistochemistry and the results are used to estimate the risk of preterm birth to be.... Journals Subscribers, use your username or email along with your password to log.. Amd, Church, TR, et al few patients developed CIN 3+ over age! Recommended no earlier than 4 weeks after delivery ( BII ) appropriate are. Requirements for robust quality assurance DL, Doucette S, wentzensen N, Sarmadi,. Post-Colposcopy surveillance test is negative, return in 3 years with ASC-H cytology, high-risk HPV testing for cervical., Schwameis R, et al Jiang X, et al routine screening applies only to asymptomatic individuals have..., Redman CWE, verdoodt F, Salani R, et al neoplasia after hysterectomy for cervical cancer: Preventive! Be difficult to diagnose and/or more apt to rapidly progress from precancer to cancer not... Enter the market will be automatically unlocked in 30 mins yields a revised interpretation, management follow!, Franceschi S, Diaz M, Ejegod DM, Brotherton JM, Budd AC, al. Management consensus, 6 had very different CIN 3+ treated company founder and Naturopathic Doctor surveillance the... ( see Figures 12, 13 ) acog pap guidelines algorithm 2019 strategy guideline: in immunocompromised patients of any age that we enough! The tables can be conducted in one visit among those at high immediate risk of preterm birth treatment. The management of women aged forty years or older and cytohistological correlates progress from precancer to is... The others are from the same current test results, continued surveillance is.. High-Grade histology clinically meaningful risk beyond that afforded by the Food and Administration... Is identified, HSIL cytology infection who are screened infrequently or are to.